Skip to main content
Premium Trial:

Request an Annual Quote

NorthBay Healthcare to Pilot GenomeSmart Genetic Test Recommendation Platform

NEW YORK — GenomeSmart said today that its GenomeBrain digital genetic test recommendation platform has been selected for pilot testing by Northern California healthcare system NorthBay Healthcare.

Launched earlier this year, GenomeBrain uses artificial intelligence to match a person's personal and medical history, as well as ethnicity and age, with national guidelines to recommended medically actionable genetic tests. The platform then generates a report that clinicians and their patients can use to determine a testing plan, according to Los Altos, California-based GenomeSmart.

Through the pilot program, NorthBay will incorporate GenomeBrain into its current workflows for breast cancer patients to help ensure they receive treatment based on genetic risk and for healthy individuals in order to expand the use of genetic testing for hereditary disease risk in routine care.

Financial and other terms of the pilot program were not disclosed.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.